Key result
Ablating both exit and nonexit sites in cardiac sarcoidosis is linked to ~75% less VT recurrence.
Why the study?
The arrhythmogenesis in cardiac sarcoidosis with ongoing inflammation is poorly understood, and the correlation of VT target sites with FDG uptake and LGE areas requires characterization.
Does targeting both exit and nonexit VT sites during ablation reduce VT recurrence in patients with cardiac sarcoidosis and active inflammation?
Cohort (n=14)
Does targeting both exit and nonexit VT sites during ablation reduce VT recurrence in patients with cardiac sarcoidosis and active inflammation?
In patients with cardiac sarcoidosis and active inflammation, identifying and ablating both exit and nonexit VT sites guided by multimodal imaging significantly reduces VT recurrence compared to targeting exit sites alone.
Answers are grounded in this paper and cite their sources.
May support broader ablation strategies beyond exit sites alone in cardiac sarcoidosis; leaves open optimal imaging-guided targets for prospective study.
BACKGROUND: The arrhythmogenesis in cardiac sarcoidosis (CS) is poorly understood. The recent ability to register fluorodeoxyglucose (FDG)-avid (FDG+) areas from positron emission tomography studies enables us to correlate the location of areas containing late gadolinium enhancement (LGE+) on cardiac magnetic resonance imaging with FDG-avid areas. OBJECTIVES: This study sought to characterize ventricular tachycardia (VT) target sites with respect to FDG uptake and to correlate with VT recurrence post-VT ablation. METHODS: In 14 patients (4 women; age 55 ± 11 years; ejection fraction 43% ± 14%) with definite CS and active inflammation referred for VT ablation, positron emission tomography and cardiac magnetic resonance findings were registered to electroanatomic maps. VT target areas were identified with pace- and entrainment-mapping, and conduction patterns were assessed based on different stimulus-QRS intervals of VA target sites. RESULTS: A total of 43 distinct VTs with 59 VT target sites were identified. A total of 88% of the identified VT target sites were in LGE+ areas, whereas 71% were in FDG+ areas. The LGE+ and FDG+ sites colocalized at 59% of all VT target sites. VT exit sites were identified for 42 of 59 VT target sites and nonexit sites for 17 of 59 VT target sites. VT exit sites were associated with FDG+ areas. During a follow-up time of 32 ± 33 months, 6 patients in whom only VT exit sites were identified had a higher VT recurrence rate than patients (n = 8) in whom both nonexit sites and exit sites for individual VTs were identified (100% vs 25%; P = 0.01), indicating that ablation at both exit and nonexit sites yielded superior results. CONCLUSIONS: In patients with CS and active inflammation, most VT target sites were confined to LGE+ and FDG+ areas. VT exit sites were associated with FDG+ areas. Patients in whom only VT exit sites were identified had higher VT recurrences.
No takes yet. Share an insight, caveat, or question.
Kovacs et al. (2026) conducted a cohort in Cardiac Sarcoidosis (n=14). Identification of only VT exit sites vs. Identification of both nonexit and exit sites was evaluated on Ventricular tachycardia recurrence (p=0.01). Identifying and ablating only VT exit sites was associated with a higher VT recurrence rate compared to identifying both exit and nonexit sites in cardiac sarcoidosis (100% vs 25%; P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: